Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: Open-label pilot study

Chest

Volumn 121, Issue 6, 2002, Pages 1860-1868

  Barst, Robyn J ^a   Rich, Stuart ^b   Widlitz, Allison ^a   Horn, Evelyn M ^a   McLaughlin, Vallerie ^b   McFarlin, Joyce ^b  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

Author keywords

Clinical trials; Endothelin; Hypertension, pulmonary; Pulmonary heart disease

Indexed keywords

ENDOTHELIN A RECEPTOR ANTAGONIST; SITAXSENTAN;

ACUTE HEPATITIS; ADOLESCENT; ADULT; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; EXERCISE TOLERANCE; FEMALE; HEART CATHETERIZATION; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; WALKING;

EID: 0036283401     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.121.6.1860     Document Type: Article

References (30)

1. Primary pulmonary hypertension
2. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
3. Vasodilator therapy for primary pulmonary hypertension in children
4. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)
5. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): Results of a randomized trial
6. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin
7. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
8. Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension
9. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: A randomised placebo-controlled study
10. Bosentan therapy for pulmonary arterial hypertension
11. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: Results of a pilot study
12. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: A randomized, controlled trial
13. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
14. Endothelin is a potent mitogen for rat vascular smooth muscle cells
15. Effects of pulmonary hypertension on vasoconstrictor responses to endothelin-1 and sarafotoxin S6C on inherent tone in rat pulmonary arteries
16. Endothelin-1 focally constricts pulmonary veins in rats
17. Effects of endothelin on regional blood flows in squirrel monkeys
18. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease?
19. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension
20. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension
21. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist
22. Endothelin antagonists: Substituted mesitylcarboxamides with high potency and selectivity for ET(A) receptors
23. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist
24. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure
25. The 6-minute walk: A new measure of exercise capacity in patients with chronic heart failure
26. Endothelin antagonists
27. Endothelin and pulmonary hypertension
28. Characterisation of the endothelin receptor mediating contraction of human pulmonary artery using BQ123 and Ro 46-2005
29. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P450 that hydoxylates the drug
30. Primary pulmonary hypertension: Executive summary from the world symposium